方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| Addenbrooke's认知检查× | 阿尔茨海默病评估量表-认知功能部分× | |
|---|---|---|
| 领域 | 神经心理学 | 神经心理学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 2000 | 1984 |
| 提出者≠ | Padasalai Mathuranath | William Rosen |
| 类型≠ | Clinician-administered comprehensive cognitive examination | Clinician-administered cognitive scale for Alzheimer's disease |
| 开创性文献≠ | Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11), 1613-1620. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| 别名≠ | ACE, ACE-R, ACE-III, Addenbrooke Cognitive Examination | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| 相关 | 5 | 5 |
| 摘要≠ | The Addenbrooke's Cognitive Examination (ACE) is a brief yet comprehensive clinician-administered cognitive battery designed to assess multiple cognitive domains and differentiate between types of dementia. Originally developed by Mathuranath and colleagues at Cambridge University in 2000, the ACE was created to address limitations of single-domain screening tools. The revised version (ACE-R, 2006) and further refined version (ACE-III, 2013) provide updated norms and improved sensitivity. The ACE-R and ACE-III are particularly valuable for distinguishing Alzheimer's disease from frontotemporal dementia. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGate数据集 ↗ |
|
|